Accuracy
A low limit of detection (LOD), high specificity (>99%), combined with frequent testing makes the SHIELD saliva-based test extremely accurate, comparable to nasal swab tests.
A low limit of detection (LOD), high specificity (>99%), combined with frequent testing makes the SHIELD saliva-based test extremely accurate, comparable to nasal swab tests.
Notification time of 6-12 hours compared to a 2-3 day turnaround time for other tests.
At a price of $30, SHIELD T3 offers significant value compared to other PCR based tests, many of which are $100 or more.
Our saliva-based test is non-invasive and does not need medically trained personnel to collect samples.
By deploying our testing via mobile labs we provide the access to testing capacity needed to support your community.
Shield T3 provides partners with a powerful tool to make an impact for their organization and community. Shield T3 is rapidly deploying to universities, and businesses across the country.
We are deploying 5 mobile labs nationally—with more on the way— to expand the reach of testing pioneered by University of Illinois researchers. The University of Illinois System has administered more than 1 million tests to date.
Shield T3 was created to expand the reach of saliva-based COVID-19 testing pioneered by researchers at the University of Illinois. Shield T3 provides a comprehensive solution to curb and control the spread of COVID-19. Our ecosystem of “Test, Tell, Target” allows early identification of infected individuals through our highly sensitive tests, enabling rapid quarantine of infected individuals, allowing organizations to take decisive action and minimize outbreaks if they occur. The breakthrough SHIELD program developed by Urbana-Champaign researchers has made UIUC one of the safest environments in North America. Our mission is to bring this capability to as many communities as possible.